1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Neuropathy – Pipeline Review, H1 2013

Neuropathy – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 77 pages

Neuropathy – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathy. Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuropathy.
- A review of the Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neuropathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neuropathy - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Neuropathy Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Neuropathy 9
Neuropathy Therapeutics under Development by Companies 11
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Neuropathy Therapeutics - Products under Development by Companies 17
Companies Involved in Neuropathy Therapeutics Development 19
The University of Texas M. D. Anderson Cancer Center 19
Novartis AG 20
Merck KGaA 21
Neuren Pharmaceuticals Limited 22
NeurogesX, Inc. 23
Allon Therapeutics Inc. 24
Lee's Pharmaceutical Holdings Limited 25
Pharnext SAS 26
MAKScientific, LLC 27
Mayo Clinic 28
TheraQuest Biosciences, LLC 29
Beech Tree Labs, Inc. 30
Eleven Biotherapeutics 31
Neuropathy - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
fingolimod hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
capsaicin - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
AL-309 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
NNZ-2591 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
NRP-2945 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
rituximab - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
minocycline - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
(gabapentin + thiamine + cobalamin) - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
flupirtine maleate - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
mepivacaine hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Drug For Toxic Neuropathies - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
acetylcarnitine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
MAC-i Class II - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Nanoparticle Complement Inhibitors - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Drug For Retinopathy/Neuropathy - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Compounds For Peripheral Neuropathy - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
AM-1710 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Neural Regeneration Peptides For Peripheral Neuropathy - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
A-836339 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Neuropathy Therapeutics - Drug Profile Updates 61
Neuropathy Therapeutics - Discontinued Products 66
Neuropathy Therapeutics - Dormant Products 67
Neuropathy - Product Development Milestones 69
Featured News and Press Releases 69
Jun 25, 2012: Baxter Announces FDA Approval For Gammagard Liquid As Treatment For Multifocal Motor Neuropathy 69
May 04, 2012: Pfizer Stops Phase III Trial Of Lyrica Capsules CV In Neuropathic Pain Associated With HIV Neuropathy 70
Apr 27, 2012: Baxter Presents Efficacy And Safety Data Evaluating Gammagard Liquid For Multifocal Motor Neuropathy At AAN Annual Meeting 70
Nov 17, 2011: Pfizer Obtains European Approval For Vyndaqel For Transthyretin Familial Amyloid Polyneuropathy 71
Apr 13, 2011: Santhera To Present Catena Clinical Study Results At 2011 American Academy Of Neurology Annual Meeting 72
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 73
Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy 74
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer 74
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 75
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77



List of Tables

Number of Products Under Development for Neuropathy, H1 2013 9
Products under Development for Neuropathy - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Development by Companies, H1 2013 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Development by Companies, H1 2013 (Contd..1) 18
The University of Texas M. D. Anderson Cancer Center, H1 2013 19
Novartis AG, H1 2013 20
Merck KGaA, H1 2013 21
Neuren Pharmaceuticals Limited, H1 2013 22
NeurogesX, Inc., H1 2013 23
Allon Therapeutics Inc., H1 2013 24
Lee's Pharmaceutical Holdings Limited, H1 2013 25
Pharnext SAS, H1 2013 26
MAKScientific, LLC, H1 2013 27
Mayo Clinic, H1 2013 28
TheraQuest Biosciences, LLC, H1 2013 29
Beech Tree Labs, Inc., H1 2013 30
Eleven Biotherapeutics, H1 2013 31
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Neuropathy Therapeutics - Drug Profile Updates 61
Neuropathy Therapeutics - Discontinued Products 66
Neuropathy Therapeutics - Dormant Products 67
Neuropathy Therapeutics - Dormant Products (Contd..1) 68



List of Figures

Number of Products under Development for Neuropathy, H1 2013 9
Products under Development for Neuropathy - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - ...

Trigeminal Neuralgia - Pipeline Review, H2 2016

Trigeminal Neuralgia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Trigeminal Neuralgia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape. ...

Optic Neuropathy - Pipeline Review, H2 2016

Optic Neuropathy - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Optic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.